Our Team

Mr. Humphries has a strong background in Dermatology, specifically in the Pharmaceutical arena and is currently the Chief Executive Officer of Isosceles Pharmaceuticals, a biotechnology company. From August 2018 until December 2020, Mr. Humphries served as President and Group Company Chairman, Ortho Dermatologics of Bausch Health Companies Inc., where he previously served as Executive Vice President, Company Group Chairman, Dermatology from January 2017 to August 2018. From 2012 to December 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2004 to 2012, he served in several leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel, a GSK Company from 2009 until 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business.

Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Uri Geiger brings extensive entrepreneurial, management and investment know-how having created and built many successful medical device enterprises. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies.

Robert “Bob” Moccia assumed the duties of Chief Executive Officer and member of the Board on March 1, 2021. Mr. Moccia has more than 20 years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies and over 35 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations. Most recently, Mr. Moccia co-founded Encore Dermatology. Prior to founding Encore, Mr. Moccia was CEO of Precision Dermatology Inc., which was sold to Valeant in 2014. Mr. Moccia has marketed and/or launched over 30 dermatological products in the US and created over $1.2B in exit transactions. He has completed multiple licenses, acquisitions and partnerships in the dermatology space. Mr. Moccia has held executive management positions at Medicis Pharmaceuticals (Sr. VP of Corporate Development), Graceway Pharmaceuticals (President & COO), and Bioglan Pharmaceuticals (President). He also spent time at Dermik and Stiefel Laboratories in sales, marketing, and business development. Mr. Moccia holds a B.S. in Biology from Stonehill College.

Samuel Rubinstein became a director of the Company effective May 29, 2018. Mr. Rubinstein joined the board of directors of Trima Pharmaceuticals in 2014 and is currently the Chairman of Trima’s board. Mr. Rubinstein served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Industries. Under his leadership Taro became a publicly traded company trading on NASDAQ and TASE, and Taro grew to become a multinational company with over 1,000 employees worldwide and turnover of close to $450 million. In 2003, Mr. Rubinstein received the Exceptional Industrialist award. He has also completed an International Marketing Course at the Wharton School of the University of Pennsylvania. Mr. Rubinstein also serves or has served in the past as a board member in various publicly traded and private companies including Clal Bio Technologies, Exalenz BioSicence, Medison Biotech, Univo Pharmaceuticals, and Tiltan Pharma (Chairman of the Board). He also serves as a consultant to BDO (Israel) and Sol-Gel Pharma. Mr. Rubinstein is also a director at the Medical Research Fund near The Tel Aviv Sourasky Medical Center and The National Authority for Yiddish Culture. We believe Mr. Rubinstein's qualifications to serve on the Board of Directors include his wealth of knowledge and industry expertise in finance, investment banking, mergers and acquisitions, equity research and investment management experience in the dermatology industry.

Mr. Strang, a partner at PwC, retired from the firm after more than 35 years of employment, at which time he was the firm’s Global Pharmaceuticals & Life Science Advisory Leader.  Mr. Strang’s career with the firm began in the audit practice, where he performed financial audits, primarily in the healthcare industry.  He later transitioned into the firm’s forensic and risk practice where he led various projects, including; board appointed financial investigations, fraud and abuse matters in the life sciences industry and other healthcare compliance regulatory matters.  He also has significant experience in the area of merger and acquisitions, where he assisted his clients with financial due diligence and merger integration.  In addition to his Global leadership role, Mr. Strang was the US Pharmaceutical and Life Sciences Advisory Leader from 2009, from which he transitioned to the European leader in 2019.  The PwC practice he led focused on providing value-added solutions across the Life Sciences value chain, including; M&A, R&D, manufacturing and supply chain, commercial and finance operations.  Mr. Strang is a Certified Public Accountant in the Commonwealth of Pennsylvania and holds a BS degree in accounting from Penn State University and an MBA from Villanova University.

Dr. Walker, a board certified dermatologist, earned both her medical degree and her Ph.D. from the University of Iowa. Following her degrees, she completed a residency in dermatology and a research fellowship in the Dermatology Branch, National Cancer Institute at the National Institute of Health (NIH).  Throughout her career, Dr. Walker has served in multiple roles in the pharmaceutical and medical device industry.  Most recently she served as the President and Chief Scientific Officer of Brickell Biotech Inc. where she oversaw the research and development, regulatory, compliance, chemistry, and manufacturing efforts for the company’s product portfolio.  Prior to that she was the Chief Medical Officer at Kythera Biopharmaceuticals. While there, she led research efforts focused on the development of novel, first in class pharmaceutical products for dermatologic and aesthetic medicine.  Before Kythera, Dr. Walker was the Chief Medical Officer at Allergan Medical where her primary research efforts catalyzed the development of alternative hyaluronic acid fillers for facial rejuvenation.  When Allergan acquired Inamed in 2006, she was Inamed’s Executive Vice President and Chief Scientific Officer.  While there, she researched biological toxins, dermal filler substances, bariatric devices, and silicone gel filled breast implants.  Dr. Walker started her Industry career at Allergan where she was the VP of the Dermatology Therapeutic Area.  She also served as a clinical faculty member at the University of California Irvine’s department of dermatology.

Most recently, Dr. Walker formed her own drug development consulting company, Walker Consulting.  She is also a practicing dermatologist in Carpinteria, California.  Dr. Walker presently serves as a supervisory board member at Merz pharmaceuticals and is on the board of directors at Forte Biosciences Inc.  Prior, she served on the board of Neothetics, Inc